Jianrong Wu

发表

Comparison of PET–CT and conventional imaging in staging pediatric rhabdomyosarcoma

Sara M. Federico, S. Spunt, B. Shulkin, 2013, Pediatric blood & cancer.

18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma

W. Reddick, Junyu Guo, A. Bahrami, 2018, Journal of Nuclear Medicine.

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

W. Reddick, J. Panetta, S. Spunt, 2012, Clinical Cancer Research.

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Michael W. Bishop, Sara M. Federico, Elizabeth Stewart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma

Sara M. Federico, Elizabeth Stewart, A. Bahrami, 2019, Clinical Cancer Research.

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Sara M. Federico, A. Pappo, R. Brennan, 2017, Clinical Cancer Research.

Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Sara M. Federico, W. Furman, Jianrong Wu, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

Li Ding, Jinghui Zhang, Matthew Parker, 2014, Cell reports.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

P. Houghton, A. Davidoff, L. McGregor, 2012, Investigational New Drugs.

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Initial testing of cisplatin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms

R. Dummer, A. Bahrami, A. Pappo, 2015, Scientific Reports.

The role of PET/CT in assessing pulmonary nodules in children with solid malignancies.

Jamie L. Coleman, M. Charron, S. Don, 2013, AJR. American journal of roentgenology.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

A. Bahrami, A. Pappo, N. Daw, 2017, International journal of cancer.

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

J. Panetta, M. Metzger, Jianrong Wu, 2016, Cancer Chemotherapy and Pharmacology.

Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors

Jing Ma, X. Su, J. Khoury, 2008, Cancer.

Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

S. Spunt, L. McGregor, W. Furman, 2015, Journal of pediatric hematology/oncology.

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

N. Daw, C. Stewart, J. Willert, 2014, Clinical Cancer Research.

Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor.

M. Williams, D. Green, A. Davidoff, 2017, Journal of pediatric surgery.

Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation.

T. Merchant, A. Davidoff, A. Nathwani, 2010, International journal of radiation oncology, biology, physics.

Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.

Sara M. Federico, A. Pappo, A. Davidoff, 2020, European journal of cancer.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

KyungMann Kim, L. McGregor, J. Allay, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

P. Houghton, C. Rodríguez-Galindo, L. McGregor, 2012, Pediatric blood & cancer.

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

P. Houghton, J. Panetta, S. Spunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.

M. Coppes, M. Chintagumpala, J. Dome, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study.

Steve Y. Cho, N. Daw, B. Shulkin, 2018, Radiology.

Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients

M. Hudson, S. Kaste, S. Howard, 2010, Cancer.

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

M. Hudson, S. Kaste, B. Shulkin, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma

W. Furman, D. Anghelescu, L. Faughnan, 2015, Pediatric blood & cancer.

Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study.

Sara M. Federico, A. Bahrami, A. Pappo, 2016 .

Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents.

P. Hinds, J. Gattuso, N. Daw, 2009, European journal of cancer.

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.

Matthew W. Wilson, C. Rodríguez-Galindo, R. Brennan, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma.

Shaum P. Bhagat, Matthew W. Wilson, C. Rodríguez-Galindo, 2010, International journal of pediatric otorhinolaryngology.

Comparison of 18F‐FDG‐PET‐CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma

A. Pappo, N. Daw, Caitlin Hurley, 2016, Pediatric blood & cancer.

Bisphosphonate Use in Pediatric Oncology for Pain Management

W. Furman, D. Anghelescu, Jianrong Wu, 2018, The American journal of hospice & palliative care.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report

Yan Chen, Zhigui Ma, Jianrong Wu, 2017, The American journal of case reports.

Initial diagnostic management of pediatric bone tumors.

A. Bahrami, A. Davidoff, A. Loh, 2015, Journal of pediatric surgery.

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program

J. Maris, P. Houghton, Malcolm A. Smith, 2015, Pediatric blood & cancer.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2015, Pediatric blood & cancer.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors

Anang A. Shelat, Elaine R. Mardis, Elizabeth Stewart, 2017, Nature.

In-bag enzymatic splenic digestion: a novel alternative to manual morcellation?

Walter H. Lang, C. Morton, J. Sandoval, 2017, The Journal of surgical research.

Curcumin Potentiates Rhabdomyosarcoma Radiosensitivity by Suppressing NF-κB Activity

L. Pfeffer, C. Morton, A. Davidoff, 2013, PloS one.

Comparison of gallium and PET scans at diagnosis and follow‐up of pediatric patients with Hodgkin lymphoma

W. Liu, M. Hudson, S. Kaste, 2008, Pediatric blood & cancer.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

S. Keir, P. Houghton, C. Morton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

J. Maris, P. Houghton, Malcolm A. Smith, 2015, Pediatric blood & cancer.

Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Pneumothorax as a Complication of Combination Antiangiogenic Therapy in Children and Young Adults with Refractory/Recurrent Solid Tumors

J. Sandoval, A. Davidoff, M. B. McCarville, 2015, Journal of pediatric surgery.

Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity

T. Merchant, C. Rodríguez-Galindo, R. Brennan, 2012, Cancer.

Initial testing of VS‐4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.

A. Davidoff, Jianrong Wu, C. Ng, 2012, Journal of pediatric surgery.

Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Influence of bony resection margins and surgicopathological factors on outcomes in limb‐sparing surgery for extremity osteosarcoma

A. Bahrami, A. Loh, N. Daw, 2015, Pediatric blood & cancer.

Case report: A rare case of TBL1XR1-RARB positive acute promyelocytic leukemia in child and review of the literature

M. Jiang, Yiping Zhu, Jianrong Wu, 2022, Frontiers in Oncology.

Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study

T. Merchant, K. Ness, D. Green, 2020 .

Time-Frequency Analysis of Transient-Evoked Otoacoustic Emissions in Children Exposed to Carboplatin Chemotherapy

Alessia Paglialonga, Gabriella Tognola, Shaum P. Bhagat, 2012, Audiology and Neurotology.

Carboplatin-associated ototoxicity in children with retinoblastoma.

T. Merchant, C. Rodríguez-Galindo, I. Qaddoumi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second neoplasms in pediatric patients with primary central nervous system tumors

C. Fuller, A. Gajjar, Jianrong Wu, 2004, Cancer.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High‐Risk Melanoma

J. Gattuso, A. Bahrami, A. Pappo, 2016, Pediatric blood & cancer.

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

Jinghui Zhang, Matthew Parker, Elaine R Mardis, 2012, JAMA.

The pediatric preclinical testing program: Description of models and early testing results

Joseph Zeidner, Javed Khan, Jian Zhang, 2007, Pediatric blood & cancer.

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

S. Keir, J. Maris, P. Houghton, 2011, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Heather L. Mulder, Michael P. Meers, Shondra M. Pruett-Miller, 2018, Nature Communications.

Safety and diagnostic accuracy of tumor biopsies in children with cancer

R. Gold, A. Bahrami, A. Pappo, 2015, Cancer.

The role of chest computed tomography (CT) as a surveillance tool in children with high‐risk neuroblastoma

Sara M. Federico, S. Brady, A. Pappo, 2015, Pediatric blood & cancer.

Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma

Sara M. Federico, M. Hudson, S. Spunt, 2015, Journal of pediatric hematology/oncology.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Peter J Houghton, John M Maris, Richard Gorlick, 2016, Cancer research.

Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

A. Davidoff, L. McGregor, W. Furman, 2010, Journal of pediatric surgery.

Telangiectatic osteosarcoma: The St. Jude Children's Research Hospital's experience

N. Daw, F. Hoffer, Jianrong Wu, 2007, Cancer.

Phase I study of everolimus in pediatric patients with refractory solid tumors.

P. Houghton, R. Gilbertson, S. Spunt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of prognostic factors in ewing sarcoma family of tumors

S. Spunt, C. Rodríguez-Galindo, N. Daw, 2007, Cancer.

Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

J. Maris, P. Houghton, Malcolm A. Smith, 2014, Pediatric blood & cancer.

Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy

W. Furman, M. B. McCarville, Jianrong Wu, 2018, International Journal of Clinical Oncology.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

S. Keir, J. Maris, O. Hampton, 2015, Pediatric blood & cancer.

Targeting the DNA repair pathway in Ewing sarcoma.

Abbas Shirinifard, Elizabeth Stewart, Andras Sablauer, 2014, Cell reports.

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Dynamic contrast‐enhanced magnetic resonance imaging as a prognostic factor in predicting event‐free and overall survival in pediatric patients with osteosarcoma

Qing Ji, Junyu Guo, W. Reddick, 2012, Cancer.

Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation

T. Merchant, C. Rodríguez-Galindo, R. Brennan, 2014, Journal of pediatric hematology/oncology.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.

N. Daw, J. Rodman, N. Marina, 2009, European journal of cancer.

Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience

N. Daw, M. Neel, Jianrong Wu, 2008, Cancer.

Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis.

A. Nienhuis, J. Gray, J. Allay, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review

A. Bahrami, A. Pappo, S. Kaste, 2015, Sarcoma.

Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Pathologic fracture in childhood and adolescent osteosarcoma: A single‐institution experience

K. Ness, S. Kaste, Jianrong Wu, 2017, Pediatric blood & cancer.

Analysis of Prognostic Factors in Extraosseous Ewing Sarcoma Family of Tumors: Review of St. Jude Children’s Research Hospital Experience

A. Davidoff, F. Navid, M. Krasin, 2012, Annals of Surgical Oncology.

Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.

P. Houghton, J. Panetta, C. Rodríguez-Galindo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized controlled trial comparing the AccuVein AV300 device to standard insertion technique for intravenous cannulation of anesthetized children

D. Anghelescu, Jianrong Wu, Jianrong Wu, 2012, Paediatric anaesthesia.

Evaluation of pediatric oncology patients with previous multiple central catheters for vascular access: Is doppler ultrasound needed?

A. Davidoff, F. Hoffer, Jianrong Wu, 2007, Pediatric blood & cancer.

Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines

Yuquan Wei, Zhigui Ma, Jianrong Wu, 2016, PloS one.

Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

IFN-β Restricts Tumor Growth and Sensitizes Alveolar Rhabdomyosarcoma to Ionizing Radiation

A. Davidoff, A. Nathwani, M. W. Gaber, 2010, Molecular Cancer Therapeutics.

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

S. Keir, L. Rubinstein, J. Maris, 2010, Molecular Cancer Therapeutics.

Mirror Therapy for Phantom Limb Pain at a Pediatric Oncology Institution

D. Anghelescu, Jianrong Wu, Huiyun Wu, 2016, Rehabilitation oncology.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2013, Pediatric blood & cancer.

Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

Sara M. Federico, A. Pappo, A. Davidoff, 2017 .

Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population

N. Daw, D. Anghelescu, M. Neel, 2017, Pediatric blood & cancer.

Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy

A. Pappo, D. Indelicato, M. Krasin, 2018, Journal of pediatric hematology/oncology.

Role of Amputation in Improving Mobility, Pain Outcomes, and Emotional and Psychological Well-Being in Children With Metastatic Osteosarcoma

J. Baker, D. Anghelescu, M. Neel, 2018, The American journal of hospice & palliative care.

Management of Local Recurrence of Pediatric Osteosarcoma Following Limb-Sparing Surgery

A. Bahrami, A. Loh, M. Neel, 2014, Annals of Surgical Oncology.

Frontline treatment of localized osteosarcoma without methotrexate

N. Daw, M. Neel, J. Jenkins, 2011, Cancer.

Timing of Surgery and the Role of Adjuvant Radiotherapy in Ewing Sarcoma of the Chest Wall: A Single-institution Experience

A. Davidoff, F. Navid, M. Krasin, 2012, Annals of Surgical Oncology.

Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.

M. Hudson, S. Donaldson, N. Tarbell, 2012, JAMA.

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Efficacy and safety of limited-margin conformal radiotherapy for pediatric rhabdomyosarcoma: long-term results of a phase II study.

T. Merchant, K. Ness, D. Green, 2020, International journal of radiation oncology, biology, physics.

The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin‐Induced Ototoxicity in Children With Cancer

M. Relling, W. Evans, J. Fang, 2013, Clinical pharmacology and therapeutics.

Gastrostomy Complications in Pediatric Cancer Patients: A Retrospective Single‐Institution Review

J. Sandoval, A. Davidoff, Jianrong Wu, 2016, Pediatric Blood & Cancer.

Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.

Jamie L. Coleman, Sara M. Federico, A. Pappo, 2017 .

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

N. Daw, C. Stewart, J. Willert, 2014, Clinical Cancer Research.

Targeting the DNA repair pathway in Ewing sarcoma.

Nathaniel R. Twarog, A. Shelat, A. Shirinifard, 2014, Cell Reports.

Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial.

M. Hudson, S. Donaldson, M. Link, 2012 .

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

P. Houghton, C. Rodríguez-Galindo, L. McGregor, 2012, Pediatric blood & cancer.

Modified Uniportal Video-Assisted Thoracic Surgery Versus Three-Port Approach for Lung Nodule Biopsy in Pediatric Cancer Patients.

A. Davidoff, Jianrong Wu, Huiyun Wu, 2019, Journal of laparoendoscopic & advanced surgical techniques. Part A.

Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

S. Spunt, L. McGregor, W. Furman, 2015, Journal of pediatric hematology/oncology.